Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3Terminated 2Withdrawn 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Tumor-Agnostic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Small Cell Lung Carcinoma 6Neoplasms 3Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Recurrence 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Head and Neck Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Neoplasms × rovalpituzumab tesirine × Clear all
NCT03000257 2022-04-14

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

AbbVie

Phase 1 Completed
182 enrolled
BreastDermatologicGastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03086239 2021-08-03

A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer

AbbVie

Phase 1 Completed
29 enrolled
Thoracic

Neoplasms, Small Cell Lung Carcinoma

NCT03543358 2021-01-05

A Long-Term Study of Rovalpituzumab Tesirine

AbbVie

Phase 2 Completed
3 enrolled 6 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡